Synthetic biology platform company programming cells for biotechnology, pharmaceuticals, agriculture, and industrial applications.
Profile & Fundamentals
Review the profile, reported financial history, AI financial assessment, dividends, splits, and dated events for Ginkgo Bioworks.
Profile & Fundamentals
Ginkgo Bioworks Profile & Fundamentals
Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Company Profile & Ownership
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Company profile record
Ginkgo Bioworks Holdings
Common Stock · Healthcare · Biotechnology
Company
- Company / asset
- Ginkgo Bioworks Holdings
- Security type
- Common Stock
- Sector
- Healthcare
- Industry
- Biotechnology
- HQ
- 🇺🇸 United States
- Head office
- 27 Drydock Avenue, Boston, MA, United States, 02210
Leadership & scale
- Chief executive
- Dr. Jason Kelly Ph.D.
- CEO year born
- 1981
- Full-time employees
- 485
- Fiscal year end
- December
- IPO date
- 2021-04-19
Fundamentals snapshot
- Market Cap
- USD 481.9M
- P/E
- --
- Revenue (Q1 26)
- USD 19.5M
- Profit (Q1 26)
- USD -82.6M
- Dividend Yield
- --
- Revenue (FY 25)
- USD 170.2M
- Shares in public float
- 47.9M
- Insider ownership
- 4.6%
Reporting & identifiers
- Symbol
- DNA.NYSE
- Listing
- 🇺🇸 United States | Dividend Tax: 30%
- Ticker Currency
- USD
- Income Statement Currency
- USD
- Balance Sheet Currency
- USD
- Cash Flow Currency
- USD
- EPS Currency
- USD
- Contract Type
- SPOT
- ISIN
- US37611X2099
- Asset ID
- equity_d620e41c-a941-50d1-953a-a198ca15eb5f
Ownership
Shares Outstanding
Latest: 59.6M | Max: 59.6M | Min: 29.0M
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open every chart, financial statement, event, and source table.